Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Taro Pharmaceutical Industries","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$3.9 million","newsHeadline":"Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis\u00ae U.S. Licensing Agreement","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"July 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Juyou Biotechnology","pharmaFlowCategory":"D","amount":"$2.9 million","upfrontCash":"$0.1 million","newsHeadline":"Crescita Announces Licensing Agreement for Pliaglis\u00ae in China","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Croma-Pharma","pharmaFlowCategory":"D","amount":"$1.4 million","upfrontCash":"Undisclosed","newsHeadline":"Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"STADA Arzneimittel","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"August 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"},{"orgOrder":0,"company":"Crescita Therapeutics","sponsor":"Egis Pharmaceuticals PLC","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"$0.7 million","newsHeadline":"Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis\u00ae","therapeuticArea":"Neurology","highestDevelopmentStatus":"Approved","country":"CANADA","productType":"Small molecule","productStatus":"Approved","date":"December 2021","url1":"","url2":"","graph1":"Neurology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Prestwick3_000571

    Menu

    Prestwick3_000571

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Crescita Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crescita Signs Exclusive 8-Country Licensing Agreement with Egis Pharmaceuticals for Pliaglis®

              Details:

              The formulation contains a eutectic mixture of 7% lidocaine and 7% tetracaine that utilizes phase-changing topical cream Peel technology. In clinical studies, the mean duration of anesthesia has been shown to be in the range of 7 to 9 hours after the application of Pliaglis.

              Lead Product(s): Lidocaine,Tetracaine

              Therapeutic Area: Neurology Product Name: Pliaglis

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Egis Pharmaceuticals PLC

              Deal Size: Undisclosed Upfront Cash: $0.7 million

              Deal Type: Licensing Agreement December 13, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Crescita Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crescita Therapeutics and STADA Enter 15-Country Exclusive Licensing Agreement for Pliaglis®

              Details:

              Under the terms of the Agreement, STADA will be responsible for commercializing Pliaglis in the Territories utilizing its experienced sales force.

              Lead Product(s): Lidocaine,Tetracaine

              Therapeutic Area: Neurology Product Name: Pliaglis

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: STADA Arzneimittel

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement August 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Crescita Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crescita Therapeutics Announces 9-Country Licensing Agreement with Croma Pharma for Pliaglis®

              Details:

              Croma will promote Pliaglis directly to physicians through its sales network consisting of approximately 130 members across the Territories. As part of the agreement, Crescita is eligible to receive a combination of upfront, cumulative sales and other milestone payments.

              Lead Product(s): Lidocaine,Tetracaine

              Therapeutic Area: Neurology Product Name: Pliaglis

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Croma-Pharma

              Deal Size: $1.4 million Upfront Cash: Undisclosed

              Deal Type: Licensing Agreement June 28, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Crescita Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crescita Announces Licensing Agreement for Pliaglis® in China

              Details:

              Under the terms of the agreement, Juyou will look after overall clinical development and regulatory filings for Pliaglis with the National Medical Products Administration (the "NMPA", formerly the China State Food and Drug Administration.

              Lead Product(s): Lidocaine,Tetracaine

              Therapeutic Area: Neurology Product Name: Pliaglis

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Juyou Biotechnology

              Deal Size: $2.9 million Upfront Cash: $0.1 million

              Deal Type: Licensing Agreement November 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Crescita Therapeutics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Crescita to Receive One-time Cash Payment Following Amendment to Pliaglis® U.S. Licensing Agreement

              Details:

              The Company continues to pursue out-licensing partnerships with focus on approximately 20 countries where Pliaglis has already received regulatory approval.

              Lead Product(s): Lidocaine,Tetracaine

              Therapeutic Area: Neurology Product Name: Pliaglis

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Taro Pharmaceutical Industries

              Deal Size: Undisclosed Upfront Cash: $3.9 million

              Deal Type: Licensing Agreement July 28, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              CHSD-Tetracaine
              Nuray Tetracaine
              Close
              4
              Post Enquiry
              POST ENQUIRY